Vanda Pharmaceuticals (VNDA) Reports Q2 Loss Per Share of 1c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results
July 29, 2015 4:02 PM EDTWASHINGTON, July 29, 2015 /PRNewswire/ --Â Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30, 2015.
"We are impressed with U.S. sales performance for both HETLIOZ and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda's President and CEO, "further investments in the commercialization and life cycle management of our products set the stage for the next level of growth for Vanda." Â
Financial Highlights
Total net product sales for the second quarter of 2015 increased by 25% over the prior... More